1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited

451.95
INR
-9.20
(-2.00%)
3.25EPS
66.13P/E
5.08BMarket Cap
Bafna Pharmaceuticals Limited
NSE:BAFNAPH
(National Stock Exchange of India)

Recent

price

451.95

P/E

ratio

66.13

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
58.09
72.68
94.92
99.03
51.86
53.53
35.5
26.04
18.44
17.95
30.07
35.99
48.76
64.45
61.66
63.67
59.43
Revenue per Share
1.92
1.04
2.14
0.75
3.28
-8.8
-10.43
-9.24
-7.98
-0.79
2.46
2.21
4.79
3.11
1.76
4.69
3.25
Basic EPS, GAAP
-5.66
-0.41
18.63
-0.08
1.53
-0.88
-0.56
-3.96
-0.9
-15.09
-8.32
0.92
-0.75
-2.69
0.12
-4.03
- -
Free Cash Flow per Basic Share
- -
- -
0.7
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
31
34.72
36.16
36.91
38.47
30.96
22.87
16.03
8.06
21.5
24
26.19
31.05
34.17
35.85
40.64
- -
Book Value per Share
31
23.59
26.4
28.37
38.46
30.94
22.85
16.02
8.04
21.5
24
26.19
30.42
33.42
35.85
40.64
- -
Tangible Book Value per Share
17
18
19
19
19
16
18
18
24
24
24
24
24
24
24
24
24
Basic Weighted Avg Shares
1,013
1,286
1,758
1,853
977
853
650
472
436
425
712
851
1,153
1,525
1,459
1,506
1,426
Sales/Revenue/Turnover
9.2
9.93
8.24
8.28
-17.44
-3.31
-14.92
-27.15
-15.72
-4.62
8.62
7.76
10.46
4.85
4.77
7.01
3.7
Operating Margin (%)
28
63
82
90
60
49
42
40
35
33
45
55
53
50
49
61
65
Depreciation Expense
33
18
40
14
62
-140
-191
-167
-189
-19
58
52
113
73
42
111
78
Net Income, GAAP
33.35
64.53
26.93
42.02
- -
- -
- -
- -
- -
- -
- -
- -
2.4
- -
- -
- -
- -
Effective Tax Rate (%)
3.31
1.43
2.25
0.76
6.32
-16.44
-29.38
-35.48
-43.25
-4.42
8.18
6.13
9.83
4.82
2.85
7.37
5.46
Profit Margin (%)
398
148
185
210
160
-23
-43
-111
-224
188
254
289
408
397
329
325
- -
Working Capital
310
263
252
229
116
352
390
232
230
30
25
53
84
108
140
178
- -
LT Debt
542
646
683
697
727
576
421
372
189
509
568
620
735
808
848
961
- -
Total Equity
7.53
1.62
2.52
0.83
- -
- -
- -
- -
- -
- -
9.9
6.28
13.97
7.37
4.57
- -
- -
Return on Invested Capital (%)
7.96
4.02
2.46
4.83
- -
- -
- -
- -
- -
- -
9.56
8.04
15.46
9.21
6.15
- -
- -
Return on Capital (%)
7.03
3.12
6.04
2.06
8.78
-21.66
-38.02
-41.53
-66.23
-5.37
10.83
8.79
16.75
9.52
5.01
12.27
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
197
- -
LT Borrowings
- -
178
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
3,565
2,587
5,077

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
897
- -
Cash, Cash Equivalents & STI
- -
37
- -
Accounts Receivable, Net
- -
439
- -
Inventories
- -
289
- -
Total Current Liabilities
- -
572
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
197
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.99%
11.21%
13.38%
Free Cash Flow
-164.61%
-737.41%
-3,551.12%
Net Income, GAAP
-26.83%
39.1%
167.3%
Sales/Revenue/Turnover
9.24%
17.23%
3.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
333
403
332
391
1,459
2026
346
355
383
422
1,506
2027
266
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.31
1.11
0.4
0.55
1.76
2026
1.43
1.32
0.78
1.16
4.69
2027
0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bafna Pharmaceuticals Limited manufactures and markets finished pharmaceutical formulations, with a focus on solid oral dosage forms including tablets, capsules, and liquids in non-betalactam, betalactam, and cephalosporin categories. The company produces over 336 licensed formulations, including key products such as Afenac-P Tab, Afenac-TH Tab, Metformin, Naproxen, and branded generics like Atorvastatin for regulated markets; it emphasizes therapeutic segments including diabetology, pain management, cardiovascular, oncology, and gastrointestinal diseases. Operations span contract manufacturing for regulated markets in the United Kingdom, Europe, and Australia, alongside exports of generics to emerging markets in Sri Lanka, Africa, the Philippines, and CIS countries, with approximately 67% of revenues from exports and 60% from contract manufacturing. Founded in 1981 and headquartered in Chennai, India, Bafna Pharmaceuticals operates as a subsidiary of SRJR Lifesciences LLP from its EU-GMP, UK-MHRA, and TGA Australia-accredited facility at Grantlyon near Chennai, serving multinational clients with around 363 employees. In recent developments, the company reported a 32.18% revenue growth to Rs. 15,246.57 lakhs in FY2023-24, driven by new formulation developments, expanded R&D and quality control capabilities, and capex plans of Rs. 50 crore through FY2025 for debottlenecking, product expansion, and maintenance. It received the MSME-ZED Gold Certificate in 2023 and the All-Round Silver Star Export Performance Award from the Pharmaceuticals Export Promotion Council of India in 2024, reflecting strengthened export focus amid plans to enter specialty formulations in regulated markets.